pazopanib pharmascience 400 mg/1 tableta filmom obložena tableta
evropa lijek pharma d.o.o. - pazopanib - filmom obložena tableta - 400 mg/1 tableta - 1 filmom obložena tableta sadrži: 400 pazopaniba (što je evivalentno 433,40 mg pazopanib hidrohlorida)
bosentan makpharm 125 mg filmom obložene tablete
makpharm d.o.o., trnjanska cesta 37/1, zagreb, hrvatska - bosentan hidrat - filmom obložena tableta - 125 mg - urbroj: jedna filmom obložena tableta sadrži 125 mg bosentana (u obliku bosentan hidrata)
bosentan makpharm 62,5 mg filmom obložene tablete
makpharm d.o.o., trnjanska cesta 37/1, zagreb, hrvatska - bosentan hidrat - filmom obložena tableta - 62,5 mg - urbroj: jedna filmom obložena tableta sadrži 62,5 mg bosentana (u obliku bosentan hidrata)
abiraterone pharmascience 500 mg/1 tableta filmom obložena tableta
evropa lijek pharma d.o.o. - abirateron - filmom obložena tableta - 500 mg/1 tableta - 1 filmom obložena tableta sadrži 500 mg abirateron acetata
abiraterone pharmascience 500 mg/1 tableta filmom obložena tableta
evropa lijek pharma d.o.o. - abirateron - filmom obložena tableta - 500 mg/1 tableta - 1 film obložena tableta sadrži 500 mg abirateron acetata
zilart 125 mg tablete za oralnu suspenziju
makpharm d.o.o., trnjanska cesta 37/1, zagreb, hrvatska - deferasiroks - tableta za oralnu suspenziju - 125 mg - urbroj: svaka tableta za oralnu suspenziju sadrži 125 mg deferasiroksa
zilart 250 mg tablete za oralnu suspenziju
makpharm d.o.o., trnjanska cesta 37/1, zagreb, hrvatska - deferasiroks - tableta za oralnu suspenziju - 250 mg - urbroj: svaka tableta za oralnu suspenziju sadrži 250 mg deferasiroksa
zilart 500 mg tablete za oralnu suspenziju
makpharm d.o.o., trnjanska cesta 37/1, zagreb, hrvatska - deferasiroks - tableta za oralnu suspenziju - 500 mg - urbroj: svaka tableta za oralnu suspenziju sadrži 500 mg deferasiroksa
dasatinib accord
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastična sredstva - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastična sredstva - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.